Rigel Pharmaceuticals Inc (RIGL) is a Healthcare · Biotechnology company listed on NASDAQ. Price $46.01 (+0.35%), Market cap $0.52B, P/E ratio 1.47, 52-week low–high $18.42 ~ $50.96.
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection
Financial statements, price targets, institutional (13F) holdings and related news for Rigel Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Rigel Pharmaceuticals Inc trades at $46.01 (+0.35%). Real-time quotes and charts are available on BlackAll Trade.
Rigel Pharmaceuticals Inc has a market cap of about $0.52B. Its P/E ratio is 1.47.
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers